Weight changes in IBD patients on infliximab and cost effects
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at how weight and body mass index (BMI) change in people with inflammatory bowel disease (IBD) who are taking infliximab, and whether these changes affect treatment costs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received infliximab for at least 14 weeks.
- You must have completed the standard starting doses at weeks 0, 2, and 6.
- You may be taking infliximab alone or with other drugs like prednisone, azathioprine, or mesalamine.
- You cannot be taking infliximab combined with tacrolimus, cyclosporine, sirolimus, mycophenolate mofetil, another biologic, or tofacitinib.
- Your medical records must have enough information for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This study looks at how being overweight affects how well treatment works for people with inflammatory bowel disease (IBD), like Crohn's or ulcerative colitis. It may help doctors understand if obesity changes outcomes or the need for stronger medications.
This study looks at different ways to measure the amount of biologic drugs in your blood. It is for people with inflammatory bowel disease who are about to start a new biologic therapy or have never taken one before.
Hear when a new Inflammatory Bowel Diseases Weight Changes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.